正大天晴品牌怎么样 申请店铺

我要投票 正大天晴在医疗用品行业中的票数:516 更新时间:2025-06-05
正大天晴是哪个国家的品牌?「正大天晴」是 正大天晴药业集团股份有限公司 旗下著名品牌。该品牌发源于江苏省连云港市,在1997年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力正大天晴品牌出海!将品牌入驻外推网,定制正大天晴品牌推广信息,可以显著提高正大天晴产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

正大天晴怎么样

正大天晴药业集团股份有限公司,创建于1997年,高新技术企业,国内较大的肝健康药物研发和生产基地,集科研、生产和销售为一体的大型医药企业


正大天晴药业集团是集科研、生产和销售为一体的创新型医药集团企业,是国内肝健康药物研发和生产基地。

正大天晴始终将科技创新作为企业发展的重要战略,是国内创新药物研究投入较多的药企之一。随着企业的发展和研发能力的提升,正大天晴的研发费用投入已超过10亿元/年,并将逐步向跨国公司看齐。目前,研究院在研项目247个,其中一类新药31个,生物药32个。

正大天晴在连云港建有三个生产基地,总占地面积800余亩,包括占地160亩的孵化基地,占地200多亩的原料药基地,占地480亩的制剂基地。正大天晴制剂基地按照欧盟和美国FDA标准设计建设,小容量注射剂获得了全国首张GMP证书,口服固体制剂获得了江苏省首张GMP证书。2014年6月,制剂基地通过欧盟认证,获得了德国药品管理局颁发的欧盟认可的GMP认证证书。目前,正大天晴正在为四大拳头产品进军国际市场做准备,未来这些药物将成为正大天晴敲开国际市场的新利器。

正大天晴产品治疗领域涉及肝病、肿瘤、呼吸、感染、消化等多种疾病领域,14个年销售过亿元的产品形成了“亿元产品群”,其中年销售额过20亿元产品2个,分别为国家一类新药异甘草酸镁注射液(天晴甘美)和国内较早上市的恩替卡韦分散片(润众)。除强势肝病领域,抗肿瘤领域也形成了独特的产品线,血液肿瘤产品地西他滨、伊马替尼、达沙替尼为国内首仿;实体瘤产品卡培他滨获批上市。呼吸、抗生素、内分泌等领域,也将是企业未来发展的方向。

未来发展中,正大天晴药业将继续强化核心竞争力的打造,建立健全科学的研发体系,使公司的研发水平始终与国际前沿接轨。



Zhengda Tianqing Pharmaceutical Group Co., Ltd., founded in 1997, is a high-tech enterprise, a large domestic R & D and production base of liver health drugs, a large pharmaceutical enterprise integrating scientific research, production and sales. Zhengda Tianqing Pharmaceutical Group is an innovative pharmaceutical group enterprise integrating scientific research, production and sales, and a domestic R & D and production base of liver health drugs. Zhengda Tianqing has always regarded scientific and technological innovation as an important strategy for the development of enterprises, and is one of the pharmaceutical enterprises with more investment in innovative drug research in China. With the development of enterprises and the improvement of R & D capabilities, the R & D investment of Zhengda Tianqing has exceeded 1 billion yuan / year, and will gradually match with that of multinational companies. At present, there are 247 research projects in the Research Institute, including 31 first-class new drugs and 32 biological drugs. Zhengda Tianqing has three production bases in Lianyungang, covering an area of more than 800 mu, including 160 Mu incubation base, more than 200 mu API base and 480 Mu preparation base. Zhengda Tianqing preparation base is designed and constructed in accordance with EU and US FDA standards. Small volume injection has obtained the first GMP certificate in China, and oral solid preparation has obtained the first GMP certificate in Jiangsu Province. In June 2014, the preparation base passed the EU certification and obtained the EU recognized GMP certification issued by the German Drug Administration. At present, Zhengda Tianqing is preparing for the four major products to enter the international market. In the future, these drugs will become a new weapon for Zhengda Tianqing to open the international market. Zhengda Tianqing's product treatment field involves various disease fields such as liver disease, tumor, respiration, infection, digestion and so on. 14 products with annual sales of more than 100 million yuan have formed a "hundred million yuan product group", including 2 products with annual sales of more than 2 billion yuan, which are the national first-class new drug magnesium isoglycate injection solution (Tianqing Ganmei) and the earlier listed entecavir dispersible tablet (Runzhong). In addition to the strong liver disease field, the anti-tumor field has also formed a unique product line. The blood tumor products sitabin, imatinib and dasatinib are the first imitations in China; the solid tumor products capecitabine have been approved for listing. Respiratory, antibiotic, endocrine and other fields will also be the future development direction of the enterprise. In the future, Zhengda Tianqing Pharmaceutical Co., Ltd. will continue to strengthen the building of core competitiveness, establish a sound scientific research and development system, and keep the company's research and development level in line with the international forefront.

本文链接: https://brand.waitui.com/31672152f.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

Rokid消费级AR眼镜将在速卖通独家首发

36氪获悉,今年海外618,Rokid最新款消费级AR眼镜将在速卖通独家首发,并加入“百亿补贴BigSave”品牌出海计划。这是速卖通AliExpress继和宇树科技机器人、安克机器人合作后,在科技品牌出海上的又一突破。今年,速卖通将通过“百亿补贴BigSave”帮助1000个新品牌实现百万美金的突破。

2小时前

半日主力资金加仓电子、通信股,抛售医药股

主力资金早间净流入电子、通信、传媒、计算机、机械设备等板块,净流出医药生物、银行、交通运输、农林牧渔、商贸零售等板块。具体到个股来看,恒宝股份、胜宏科技、中际旭创获净流入9.28亿元、7.00亿元、6.20亿元。净流出方面,德邦股份、宁德时代、比亚迪遭抛售6.44亿元、3.12亿元、2.90亿元。(第一财经)

2小时前

阿里橙狮体育在上海成立体育新公司,注册资本200万元

36氪获悉,爱企查App显示,近日,上海松江乐动力体育有限公司成立,法定代表人为彭铿,注册资本200万元人民币,经营范围包括食品销售、演出经纪、体育场地设施经营、人工智能硬件销售、智能机器人销售等。股东信息显示,该公司由橙狮体育有限公司全资持股。

2小时前

淘宝天猫推出官方物流品牌“极速上门”,联合顺丰开启首期服务公测

36氪获悉,近日淘宝天猫官方物流迎重大升级,于天猫618期间上线高品质物流服务品牌“极速上门”,首期联合顺丰作为快递合作伙伴,并同步邀请部分商家开启服务公测。使用顺丰速运并达到次日达服务标准的商品,物流服务将展示“极速上门”专属品牌标识。此外所有商家在后台配置承诺发顺丰的商品,将展示“顺丰包邮、送货上门”等强时效表达。这是淘宝继打击羊毛党、治理恶意店群、取消仅退款等系列“扶优去劣”举措后,在物流领域的重点突破,持续改善商家营商环境。

2小时前

吉利等在辽宁成立远醇能源新公司,注册资本4000万元

36氪获悉,爱企查App显示,近日,辽宁远醇能源有限公司成立,法定代表人为姜丽,注册资本4000万元人民币,经营范围包括新兴能源技术研发、新能源汽车整车销售、供应链管理服务等。股权穿透图显示,该公司由沈阳大龙洋石油有限公司、浙江吉利控股集团有限公司旗下浙江绿动醇氢科技服务有限公司共同持股。

2小时前

本页详细列出关于正大天晴的品牌信息,含品牌所属公司介绍,正大天晴所处行业的品牌地位及优势。
咨询